Cellular reprogramming: a new approach to modelling Parkinson's disease.

Cellular reprogramming: a new approach to modelling Parkinson's disease.

iPSCs (induced pluripotent stem cells) offer an unparalleled opportunity to generate and study physiologically relevant cell types in culture. iPSCs can be generated by reprogramming almost any somatic cell type using pluripotency factors such as Oct4, SOX2, Nanog and Klf4. By reprogramming cells fr...

Πλήρης περιγραφή

Λεπτομέρειες βιβλιογραφικής εγγραφής
Κύριοι συγγραφείς:	Hartfield, E, Fernandes, H, Vowles, J, Cowley, S, Wade-Martins, R
Μορφή:	Journal article
Γλώσσα:	English
Έκδοση:	2012

Παρόμοια τεκμήρια

Physiological characterisation of human iPS-derived dopaminergic neurons
ανά: Hartfield, E, κ.ά.
Έκδοση: (2014)

Physiological characterisation of human iPS-derived dopaminergic neurons
ανά: Hartfield, E, κ.ά.
Έκδοση: (2014)

Parkinson's disease in a dish - Using stem cells as a molecular tool.
ανά: Badger, J, κ.ά.
Έκδοση: (2014)

Parkinson's disease in a dish - Using stem cells as a molecular tool
ανά: Badger, J, κ.ά.
Έκδοση: (2014)

Cellular α-synuclein pathology is associated with bioenergetic dysfunction in Parkinson's iPSC-derived dopamine neurons
ανά: Zambon, F, κ.ά.
Έκδοση: (2019)

Protein-protein interaction networks identify targets which rescue the MPP+ cellular model of Parkinson's disease
ανά: Keane, H, κ.ά.
Έκδοση: (2015)

Variant U1 snRNAs are implicated in human pluripotent stem cell maintenance and neuromuscular disease.
ανά: Vazquez-Arango, P, κ.ά.
Έκδοση: (2016)

Physiological characterisation of human iPS-derived dopaminergic neurons.
ανά: Elizabeth M Hartfield, κ.ά.
Έκδοση: (2014-01-01)

Transcriptomic profiling of purified patient-derived dopamine neurons identifies convergent perturbations and therapeutics for Parkinson's disease.
ανά: Sandor, C, κ.ά.
Έκδοση: (2017)

Cell reprogramming therapy for Parkinson’s disease
ανά: Wenjing Dong, κ.ά.
Έκδοση: (2024-01-01)

ER stress and autophagic perturbations lead to elevated extracellular α-Synuclein in GBA-N370S Parkinson's iPSC-derived dopamine neurons
ανά: Fernandes, H, κ.ά.
Έκδοση: (2016)

Cellular reprogramming for understanding and treating human disease.
ανά: Riya Rajan Kanherkar, κ.ά.
Έκδοση: (2014-11-01)

Neuroprotective Effects of Cryptotanshinone in a Direct Reprogramming Model of Parkinson’s Disease
ανά: Joo-Eun Lee, κ.ά.
Έκδοση: (2020-08-01)

Epigenetic Dynamics in Reprogramming to Dopaminergic Neurons for Parkinson's Disease
ανά: Byounggook Cho, κ.ά.
Έκδοση: (2024-11-01)

Astrocyte-to-neuron reprogramming and crosstalk in the treatment of Parkinson's disease
ανά: Yiming Wang, κ.ά.
Έκδοση: (2023-08-01)

Commentary: Parkinson disease-linked GBA mutation effects reversed by molecular chaperones in human cell and fly models
ανά: Fernandes, H, κ.ά.
Έκδοση: (2017)

Are rodent models of Parkinson's disease behaving as they should?
ανά: Vingill, S, κ.ά.
Έκδοση: (2017)

Cellular Reprogramming and Its Potential Application in Alzheimer’s Disease
ανά: Chao Zhou, κ.ά.
Έκδοση: (2022-04-01)

Network pharmacology of the MPP+ cellular model of Parkinson’s disease
ανά: Keane, H
Έκδοση: (2015)

RNA sequencing reveals MMP2 and TGFB1 downregulation in LRRK2 G2019S Parkinson's iPSC-derived astrocytes
ανά: Booth, H, κ.ά.
Έκδοση: (2019)

Programming and reprogramming cellular identity
ανά: Marson, Alexander
Έκδοση: (2008)

Re: Epigenetics of Cellular Reprogramming
ανά: Fehmi Narter
Έκδοση: (2016-12-01)

Deterministic versus stochastic model of reprogramming: new evidence from cellular barcoding technique
ανά: Anastasia M. Yunusova, κ.ά.
Έκδοση: (2017-01-01)

Convergent pathways in Parkinson’s disease
ανά: Cherubini, M, κ.ά.
Έκδοση: (2017)

Advances in Cellular Reprogramming-Based Approaches for Heart Regenerative Repair
ανά: Xingyu He, κ.ά.
Έκδοση: (2022-12-01)

Potential cellular and regenerative approaches for the treatment of Parkinson&rsquo;s disease
ανά: Emma L Lane, κ.ά.
Έκδοση: (2008-08-01)

Cellular Reprogramming toward the Erythroid Lineage
ανά: Laura J. Norton, κ.ά.
Έκδοση: (2011-01-01)

Single-cell sequencing of iPSC-dopamine neurons reconstructs disease progression and identifies HDAC4 as a regulator of Parkinson cell phenotypes
ανά: Lang, C, κ.ά.
Έκδοση: (2018)

Epigenetic reprogramming shapes the cellular landscape of schwannoma
ανά: S. John Liu, κ.ά.
Έκδοση: (2024-01-01)

Epigenetic determinants of cellular differentiation, transcriptional reprogramming, and human disease
ανά: Nguyen, Khoi Thien.
Έκδοση: (2021)

The Importance of Ubiquitination and Deubiquitination in Cellular Reprogramming
ανά: Bharathi Suresh, κ.ά.
Έκδοση: (2016-01-01)

Dynamical systems theory of cellular reprogramming
ανά: Yuuki Matsushita, κ.ά.
Έκδοση: (2022-04-01)

Cellular programming and reprogramming - Methods and protocols
ανά: CarloAlberto Redi
Έκδοση: (2010-12-01)

Implications of Cellular Aging in Cardiac Reprogramming
ανά: Fabiana Passaro, κ.ά.
Έκδοση: (2018-04-01)

Neuroregeneration using in vivo cellular reprogramming
ανά: Tu Nguyen, κ.ά.
Έκδοση: (2017-01-01)

The role of astrocyte dysfunction in Parkinson's disease pathogenesis
ανά: Booth, H, κ.ά.
Έκδοση: (2017)

Induced pluripotent stem cell (iPSC)-derived dopaminergic models of Parkinson's disease.
ανά: Beevers, J, κ.ά.
Έκδοση: (2013)

Parkinson’s Disease in a Dish: What Patient Specific-Reprogrammed Somatic Cells Can Tell Us about Parkinson’s Disease, If Anything?
ανά: J. Drouin-Ouellet, κ.ά.
Έκδοση: (2012-01-01)

Exploring the Mitochondrial Degradome by the TAILS Proteomics Approach in a Cellular Model of Parkinson’s Disease
ανά: Marta Lualdi, κ.ά.
Έκδοση: (2019-07-01)

New roles of glycosaminoglycans in α-synuclein aggregation in a cellular model of Parkinson disease.
ανά: Sonia Lehri-Boufala, κ.ά.
Έκδοση: (2015-01-01)